CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 11, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the BIO InvestorForum 2006 on October 18, 2006 at 1:40 p.m. (PT) at The Palace Hotel, San Francisco, California.

A live audio webcast of these presentations will be available on the "Investors" section of the company's website, www.alnylam.com. A replay of the presentations will be posted on the Alnylam website approximately three hours after each event, and will be archived for 30 days.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the "emerging/mid-cap" company recipient of the 2006 James D. Watson Helix Award, the biotechnology industry's award for outstanding achievement. For more information, visit www.alnylam.com.

    CONTACT: Investors:
             Alnylam Pharmaceuticals, Inc.
             Cynthia Clayton, 617-551-8207
             or
             Media:
             KMorrisPR
             Kathryn Morris, 845-635-9828

    SOURCE: Alnylam Pharmaceuticals, Inc.